Clearside Biomedical develops ophthalmic drug-delivery technology for therapies administered to the back of the eye through the suprachoroidal space. News about CLSD centers on the SCS Microinjector platform, the CLS-AX axitinib injectable suspension program for retinal diseases, XIPERE approvals and partner use of the company's suprachoroidal injection technology.
Company updates also cover licensing collaborations, medical-meeting presentations, financial results, Nasdaq listing matters, strategic-alternative reviews and the company's voluntary Chapter 11 restructuring process. These items frame Clearside as a biopharmaceutical issuer built around suprachoroidal delivery, ophthalmology development programs and royalty-related platform assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.